About Empress:
Empress is a privately-held early-stage biotech company advancing a proprietary platform to generate small molecule drugs faster and more predictably.
Position Summary:
Empress is looking for a (senior) data scientist, Proteomics/Metabolomics to operate on a contract basis. Estimated contract is 6 months at 20 hours per week.
Key Responsibilities:
- Work closely with our in-house AWS infrastructure and pipeline teams to bring scale and automation to your code.
- Consider the path from our data types (metabolomics, proteomics, phosphoproteomics, chemoproteomics) to our necessary inference.
- Propose and champion solutions at all stages of this process – data generation to processing to inference – employing statistical modeling and machine learning approaches to augment our understanding.
- Improve and leverage our existing raw data processing pipelines for DDA metabolomics, DDA proteomics, and DIA proteomics.
- Collaborate closely with our chemoproteomics, synthetic biology, and metabolomics teams to build tools for the analysis, visualization, and reporting of data.
Qualifications:
- Ph.D. with 1+ years or M.S. with 3+ years of relevant data science and software development experience
- High level of proficiency in programming languages such as Python and/or R.
- Familiarity with mass spectrometry software and databases (e.g., Proteome Discoverer, Skyline, Compound Discoverer).
- Experience working with biological and mass spectrometry data types including chemoproteomics, proteomics, metabolomics, and natural product structures
- Experience applying statistical and machine learning methods
- Extremely collaborative, innovative, and driven to add value to diverse projects across Empress
About Flagship
Flagship Pioneering is a bioplatform innovation company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in generation of over 500 patents, initiation of over 50 clinical trials for novel therapeutic agents and an aggregate value of more than $90 billion. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture. Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com.
Flagship Pioneering is committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.
Similar Jobs
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions. The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
